News Astellas pays $285m for Audax cancer drug, and other deals Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.
R&D Removing barriers in treatment-resistant depression pharmaphorum speaks with Hans Eriksson, psychiatrist and CMO of FundaMental Pharma, about why treatment resistance remains such a challenge.
News GLP-1 drugs linked to reduced acute schizophrenia episodes The list of illnesses that may benefit from treatment with GLP-1 drugs gets ever longer, and a study has found that schizophrenia may be an addition.
Patients In schizophrenia care, even the support system needs support After a schizophrenia diagnosis, families must learn how to navigate treatment, respond to symptoms, and communicate effectively.
Digital Callyope's AI-powered solution for mental health practitione... The state of the public’s mental health in the UK and Europe is a serious unmet need.
Patients Stronger together: The future of psychiatry in a changing Eu... Mental disorders account for a significant share of economic cost across EU Member States and the United Kingdom.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.